Barr's Generic Biologics Strategy Includes Outsourcing Manufacturing
This article was originally published in The Pink Sheet Daily
Executive Summary
The value of generic biologics will not come from manufacturing but rather from "navigating the regulatory and legal arena," CEO Downey says. Barr plans to detail its business plan by next June.